Sana Biotechnology, Inc. (SANA)
2.33
-0.04
(-1.69%)
USD |
NASDAQ |
Oct 23, 16:00
2.32
-0.01
(-0.43%)
After-Hours: 20:00
Sana Biotechnology Enterprise Value : 606.44M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 606.44M |
| October 22, 2026 | 618.41M |
| October 21, 2026 | 612.42M |
| October 20, 2026 | 615.42M |
| October 19, 2026 | 597.46M |
| October 16, 2026 | 588.48M |
| October 15, 2026 | 649.84M |
| October 14, 2026 | 606.44M |
| October 13, 2026 | 630.38M |
| October 12, 2026 | 693.24M |
| October 09, 2026 | 744.12M |
| October 08, 2026 | 744.12M |
| October 07, 2026 | 723.17M |
| October 06, 2026 | 732.15M |
| October 05, 2026 | 771.06M |
| October 02, 2026 | 774.05M |
| October 01, 2026 | 774.05M |
| September 30, 2026 | 781.53M |
| September 29, 2026 | 780.03M |
| September 28, 2026 | 786.02M |
| September 25, 2026 | 790.51M |
| September 24, 2026 | 795.00M |
| September 23, 2026 | 830.92M |
| September 22, 2026 | 905.74M |
| September 21, 2026 | 836.90M |
| Date | Value |
|---|---|
| September 18, 2026 | 836.90M |
| September 17, 2026 | 836.90M |
| September 16, 2026 | 783.03M |
| September 15, 2026 | 854.86M |
| September 14, 2026 | 866.83M |
| September 11, 2026 | 845.88M |
| September 10, 2026 | 833.91M |
| September 09, 2026 | 857.85M |
| September 08, 2026 | 941.66M |
| September 04, 2026 | 1.061B |
| September 03, 2026 | 1.082B |
| September 02, 2026 | 1.073B |
| September 01, 2026 | 1.055B |
| August 31, 2026 | 1.067B |
| August 28, 2026 | 1.085B |
| August 27, 2026 | 1.133B |
| August 26, 2026 | 1.154B |
| August 25, 2026 | 1.136B |
| August 24, 2026 | 1.040B |
| August 21, 2026 | 1.079B |
| August 20, 2026 | 1.028B |
| August 19, 2026 | 1.136B |
| August 18, 2026 | 995.53M |
| August 17, 2026 | 1.011B |
| August 14, 2026 | 971.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.205B |
| Twist Bioscience Corp. | 8.696B |
| Beam Therapeutics, Inc. | 1.578B |
| Revolution Medicines, Inc. | 37.31B |
| Prelude Therapeutics, Inc. | 155.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -63.64M |
| Total Expenses (Quarterly) | 63.64M |
| EPS Diluted (Quarterly) | -0.2152 |
| Earnings Yield | -32.65% |
| Normalized Earnings Yield | -29.12 |